[go: up one dir, main page]

WO2004108141A3 - Bach-o-protein coupled receptor releated methods - Google Patents

Bach-o-protein coupled receptor releated methods Download PDF

Info

Publication number
WO2004108141A3
WO2004108141A3 PCT/GB2004/002301 GB2004002301W WO2004108141A3 WO 2004108141 A3 WO2004108141 A3 WO 2004108141A3 GB 2004002301 W GB2004002301 W GB 2004002301W WO 2004108141 A3 WO2004108141 A3 WO 2004108141A3
Authority
WO
WIPO (PCT)
Prior art keywords
gpcr
adp
pain
bach
migraine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2004/002301
Other languages
French (fr)
Other versions
WO2004108141A2 (en
Inventor
Samuel Aparicio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Paradigm Therapeutics Ltd
Original Assignee
Paradigm Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paradigm Therapeutics Ltd filed Critical Paradigm Therapeutics Ltd
Publication of WO2004108141A2 publication Critical patent/WO2004108141A2/en
Publication of WO2004108141A3 publication Critical patent/WO2004108141A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

We disclose that ADP is capable of binding to and activating the BACH-Gprotein coupled receptor (BACCH-GPCR). We describe methods of identifying a compound or an agent which is capable of modulating the ability of ADP to activate the BACK-GPCR. We also describe using ADP or derivatives thereof or modulators of the binding between ADP and the BACK-GPCR for treating diseases associated with BACH-GPCR consisting of trigeminal neuralgia, pain of various origins, irritable bowel syndrome, bladder instability, Barrett’s esophagus, glaucoma, pain associated with cancer, diabetic neuropathies, Herpes virus infections, migraine and skin sensitivity associated with migraine, allodynia, toothache, neuroma, dementia, dyslexia, dyskinesias, tremor, Parkinson’s, benign essential tremor, chorea, epilepsy or ballismus, for example occurring through stroke, trauma, degeneration and malignancy, chronic pain (peripheral or visceral) and relapsing remitting pain such as migraine, dry eye disorder, cyctic fibrosis, hyperactive bladder, hypercholesterolaemia, dislipdaemias and obesity.
PCT/GB2004/002301 2003-06-04 2004-06-01 Bach-o-protein coupled receptor releated methods Ceased WO2004108141A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0312844,4 2003-06-04
GBGB0312844.4A GB0312844D0 (en) 2003-06-04 2003-06-04 Use of compounds in medicine

Publications (2)

Publication Number Publication Date
WO2004108141A2 WO2004108141A2 (en) 2004-12-16
WO2004108141A3 true WO2004108141A3 (en) 2005-03-31

Family

ID=9959315

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/002301 Ceased WO2004108141A2 (en) 2003-06-04 2004-06-01 Bach-o-protein coupled receptor releated methods

Country Status (2)

Country Link
GB (1) GB0312844D0 (en)
WO (1) WO2004108141A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2180916B1 (en) * 2007-07-30 2014-10-01 University Of Rochester Adenosine as a therapeutic tool to improve the efficacy of deep brain stimulation
ITTO20110576A1 (en) 2011-06-30 2012-12-31 Medicam Health Science S R L COMPOSITION INCLUDING THE ASSOCIATION OF MELISSA PHYTO-EXTRACT, METHYLAMIDE AND A SOURCE OF NUCLEOTIDES AND / OR NUCLEOSIDES AND ITS USE IN THE TREATMENT OF HEADACHE AND HEMICRYANES
US20210148918A1 (en) * 2018-04-17 2021-05-20 Purdue Research Foundation Modifying surface of a live cell and the uses thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5547942A (en) * 1994-01-04 1996-08-20 Rapaport; Eliezer Method of treatment of diabetes mellitus by administration of adenosine 5'-t
WO2001043733A2 (en) * 1999-12-15 2001-06-21 Levin Bruce H Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation
WO2001045691A2 (en) * 1999-12-22 2001-06-28 Inspire Pharmaceuticals, Inc. Method of treating gastrointestinal tract disease with purinergic receptor agonists
WO2002038607A2 (en) * 2000-11-07 2002-05-16 Paradigm Therapeutics Limited A 'bach' g protein coupled receptor polypeptide and polynucleotide encoding this receptor
US6440455B1 (en) * 1997-09-02 2002-08-27 Children's Medical Center Corporation Methods for modulating the axonal outgrowth of central nervous system neurons
WO2003014731A2 (en) * 2001-08-07 2003-02-20 Euroscreen S.A. The natural ligand for orphan g protein coupled receptor gpr86 and methods of use
US20030059857A1 (en) * 2001-09-17 2003-03-27 Schering Corporation G-protein coupled receptor and methods

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5547942A (en) * 1994-01-04 1996-08-20 Rapaport; Eliezer Method of treatment of diabetes mellitus by administration of adenosine 5'-t
US6440455B1 (en) * 1997-09-02 2002-08-27 Children's Medical Center Corporation Methods for modulating the axonal outgrowth of central nervous system neurons
WO2001043733A2 (en) * 1999-12-15 2001-06-21 Levin Bruce H Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation
WO2001045691A2 (en) * 1999-12-22 2001-06-28 Inspire Pharmaceuticals, Inc. Method of treating gastrointestinal tract disease with purinergic receptor agonists
WO2002038607A2 (en) * 2000-11-07 2002-05-16 Paradigm Therapeutics Limited A 'bach' g protein coupled receptor polypeptide and polynucleotide encoding this receptor
WO2003014731A2 (en) * 2001-08-07 2003-02-20 Euroscreen S.A. The natural ligand for orphan g protein coupled receptor gpr86 and methods of use
US20030059857A1 (en) * 2001-09-17 2003-03-27 Schering Corporation G-protein coupled receptor and methods

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DOL-GLEIZES F ET AL: "Relaxant effect of 2-methyl-thio-adenosine diphosphate on rat thoracic aorta: effect of clopidogrel.", EUROPEAN JOURNAL OF PHARMACOLOGY. 19 FEB 1999, vol. 367, no. 2-3, 19 February 1999 (1999-02-19), pages 247 - 253, XP001202603, ISSN: 0014-2999 *
OGATA TADANORI ET AL: "Adenosine triphosphate inhibits cytokine release from lipopolysaccharide-activated microglia via P2y receptors.", BRAIN RESEARCH. 15 AUG 2003, vol. 981, no. 1-2, 15 August 2003 (2003-08-15), pages 174 - 183, XP001202601, ISSN: 0006-8993 *

Also Published As

Publication number Publication date
GB0312844D0 (en) 2003-07-09
WO2004108141A2 (en) 2004-12-16

Similar Documents

Publication Publication Date Title
WO2007021647A3 (en) Method for treating myocradial rupture
EP4620469A3 (en) Tricyclic urea compounds as jak2 v617f inhibitors
WO2004103960A3 (en) Compounds and uses thereof
WO2008124083A3 (en) Aurora kinase modulators and method of use
WO2009017104A1 (en) Protective agent against damage of biological tissue caused by near-infrared ray, and product comprising the same
BRPI0514005A (en) compound, pharmaceutical composition, use of a compound, method for treating or preventing neurological and psychiatric disorders associated with glutamate dysfunction in an animal, and process for preparing a compound
BRPI0518173A8 (en) ophthalmic compositions
WO2003073823A3 (en) PDPK1s AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2004108141A3 (en) Bach-o-protein coupled receptor releated methods
WO2006047466A3 (en) Ophthamological drugs
WO2007033082A3 (en) Compositions comprising dimethyl sulfoxide (dmso)
WO2023129738A3 (en) Modified polysaccharide polymers and related compositions and methods thereof
Tishchenko et al. Low-molecular-weight chitosans: Preparation and characterization
WO2007137236A3 (en) Drug loaded contrast agents: combining diagnosis and therapy
WO2010062975A3 (en) Suppressor of ap-1
JP2017519570A (en) Needleless injection device with fixed double membrane
EP1903083A4 (en) (meth)acrylic emulsion type pressure-sensitive adhesive composition and pressure-sensitive adhesive sheet
RU93036396A (en) COMBAT PART
WO2003070965A3 (en) The eaat2 promoter and uses thereof
Curcio et al. Antioxidant polymers by free radical grafting on natural polymers
EP2046306B8 (en) Coating composition comprising starch
WO2004037992A3 (en) Mapk7 as modifier of branching morphogenesis and methods of use
BR0206203A (en) Aqueous multicomponent coating material, its preparation and use
WO2007002087A3 (en) Cdc6s as modifiers of the pten/akt pathway and methods of use
WO2007037859A3 (en) Clearcoat paint composition

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase